Health Technology

SAMSUNG BIOLOGICS Co., Ltd.

In the news

Samsung Biologics to invest $1.5bn for new pharmaceutical plant Aug 11, 2020
Samsung Biologics snags $1.5bn in orders on pandemic rush Jun 29, 2020
Toyota AGM, Macao casino regulator, Vietnam-EU trade deal Jun 7, 2020
South Korea seeks arrest of Samsung heir in succession probe Jun 4, 2020
Kakao tops Hyundai in market cap as pandemic shakes up Korea Inc. May 25, 2020

See more articles on SAMSUNG BIOLOGICS Co., Ltd.

Business Summary

SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. The company was founded on April 22, 2011 and is headquartered in Incheon, South Korea.

Financial Highlights

Dec 2021	KRW	USD
Revenue	1,568.00B	1,369.24M
Gross Profit	784,969.49M	685.46M
Operating income	537,309.40M	469.20M
Income before tax	547,429.45M	478.03M
Net income	393,589.46M	343.69M
EBITDA	699,098.05M	610.48M
Diluted EPS	5,886.12	5.14
Dividends Per Share	0	0
Total Assets	7,970.01B	6,704.53M
Total liabilities	2,978.90B	2,505.91M
Total equity	4,991.10B	4,198.61M
Operating cash flow	454,596.21M	396.97M
	Currency in KRW	Currency in USD

Historical Data

KRW | USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021
Revenue	464,629.33M	535,805.80M	701,591.85M	1,164.77B	1,568.00B
Gross Profit	122,304.94M	130,544.55M	230,536.76M	469,262.42M	784,969.49M
Operating income	65,979.40M	55,678.74M	92,084.47M	293,299.68M	537,309.40M
Income before tax	-115,994.75M	302,975.83M	82,495.19M	283,759.85M	547,429.45M
Net income	-96,972.11M	224,109.19M	202,904.09M	240,974.79M	393,589.46M
EBITDA	135,905.62M	147,129.29M	224,627.48M	436,474.55M	699,098.05M
Diluted EPS	-1,450.60	3,351.42	3,034.42	3,603.77	5,886.12
Dividends Per Share	0	0	0	0	0
Total Assets	7,183.09B	5,980.40B	5,911.62B	6,424.20B	7,970.01B
Total liabilities	3,206.64B	1,824.94B	1,557.17B	1,825.41B	2,978.90B
Total equity	3,976.45B	4,155.46B	4,354.45B	4,598.78B	4,991.10B
Operating cash flow	149,816.32M	36,787.30M	10,153.61M	202,090.02M	454,596.21M

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021
Revenue	410.99M	486.86M	601.61M	987.19M	1,369.24M
Gross Profit	108.18M	118.62M	197.68M	397.71M	685.46M
Operating income	58.36M	50.59M	78.96M	248.58M	469.20M
Income before tax	-102.60M	275.30M	70.73M	240.49M	478.03M
Net income	-85.77M	203.63M	173.98M	204.23M	343.69M
EBITDA	120.21M	133.69M	192.61M	369.92M	610.48M
Diluted EPS	-1.28	3.04	2.60	3.05	5.14
Dividends Per Share	0	0	0	0	0
Total Assets	6,709.72M	5,359.74M	5,111.87M	5,913.83M	6,704.53M
Total liabilities	2,995.32M	1,635.54M	1,346.51M	1,680.39M	2,505.91M
Total equity	3,714.39M	3,724.20M	3,765.36M	4,233.43M	4,198.61M
Operating cash flow	132.52M	33.42M	8.70M	171.27M	396.97M

Valuation Measures

Dec 2021
PER	151.80
ROA	5.46%
ROE	8.20%
Operating margin	34.26%
Profit margin	25.10%

Key executives

President, Chief Executive Officer & Director: John Chongbo Rim
Head-Finance & Vice President: Doyoung Heo
Managing Director & Head-Process Technology: Yong-Ho An
Head-Compliance Support: Hyung-Woo Moon
Executive Vice President: Kyu-Sung Lee

Shareholders

Samsung C&T Corp. (43.0%)
Samsung Electronics Co., Ltd. (31.2%)
National Pension Service of Korea (5.6%)
Invesco Advisers, Inc. (1.0%)
The Vanguard Group, Inc. (0.6%)
BlackRock Fund Advisors (0.6%)
Samsung Asset Management Co., Ltd. (0.4%)
Norges Bank Investment Management (0.2%)
Fidelity Management & Research Co. LLC (0.2%)
Mirae Asset Global Investments Co., Ltd. (0.2%)

Contact Details

Website:http://www.samsungbiologics.com
Address: 300 Songdo Bio Way, Yeonsu-gu, Inchon, 21987, South Korea
Phone: +82.32.455.3114

Related Companies

Samsung Biologics America, Inc.
Samsung BioLogics Co., Ltd. ESOA
Samsung Romania

Competitors

Lonza Group AG
Wuxi Biologics (Cayman) Inc.
FUJIFILM Holdings Corp
PanGen Biotech, Inc.
EirGenix Inc
Binex Co., Ltd
Celltrion, Inc.
Bukwang Pharmaceutical Co., Ltd.
Celltrion Healthcare Co., Ltd.
Coherus BioSciences, Inc.
EPIRUS Biopharmaceuticals, Inc.
Greenwich LifeSciences, Inc.
Kodiak Sciences, Inc.
PharmAbcine Inc.
PharmGen Science, Inc.
Prestige Biologics Co., Ltd.
Regeneron Pharmaceuticals, Inc.
Reyon Pharmaceutical Co., Ltd.
SCM LIFESCIENCE CO., LTD

Last Updated on 27 Jan, 2023